Use of a neutralizing antibody helps identify structural features critical for binding of Clostridium difficile toxin TcdA to the host cell surface

Journal of Biological Chemistry

Volumn 292, Issue 35, 2017, Pages 14401-14412

  Kroh, Heather K ^a   Chandrasekaran, Ramyavardhanee ^a   Rosenthal, Kim ^b   Woods, Rob ^b   Jin, Xiaofang ^b   Ohi, Melanie D ^a   Nyborg, Andrew C ^b   Rainey, G Jonah ^d   Warrener, Paul ^b   Spiller, Benjamin W ^a   Lacy, D Borden ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDIMMUNE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d MabVax Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MEMBRANES; CLOSTRIDIUM; CROPS; CRYSTAL STRUCTURE; CYTOLOGY; LIGHT SCATTERING; MOLECULAR BIOLOGY; MONOCLONAL ANTIBODIES; TOXIC MATERIALS;

CARBOHYDRATE BINDING; CLOSTRIDIUM DIFFICILE; GLUCOSYLTRANSFERASES; MECHANISM OF ACTION; MOLECULAR MECHANISM; MULTI-ANGLE LIGHT SCATTERINGS; MULTI-STEP MECHANISM; NEUTRALIZING ANTIBODIES;

BINDING SITES;

BACTERIAL TOXIN; CLOSTRIDIUM DIFFICILE TOXIN TCDA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PA50; NEUTRALIZING ANTIBODY; OLIGOPEPTIDE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; ENTEROTOXIN; GLUCOSYLTRANSFERASE; IMMUNOGLOBULIN F(AB) FRAGMENT; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE;

ARTICLE; BINDING SITE; CACO-2 CELL LINE; CARBOXY TERMINAL SEQUENCE; CELL SURFACE; COLON EPITHELIUM; CONTROLLED STUDY; CRYSTAL STRUCTURE; ELECTRON MICROSCOPY; EPITHELIUM CELL; HOST CELL; HUMAN; HUMAN CELL; LIGHT SCATTERING; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; STOICHIOMETRY; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY; AMINO ACID REPEAT; AMINO ACID SEQUENCE; ANTIBODY COMBINING SITE; CHEMISTRY; CONSERVED SEQUENCE; DRUG EFFECTS; ENZYMOLOGY; EPITOPE MAPPING; GENETICS; INTESTINE CELL; METABOLISM; MOLECULAR MODEL; PROTEIN CONFORMATION;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; BACTERIAL PROTEINS; BACTERIAL TOXINS; BINDING SITES, ANTIBODY; CACO-2 CELLS; CLOSTRIDIUM DIFFICILE; CONSERVED SEQUENCE; CRYSTALLOGRAPHY, X-RAY; ENTEROCYTES; ENTEROTOXINS; EPITOPE MAPPING; GLUCOSYLTRANSFERASES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECOMBINANT PROTEINS; REPETITIVE SEQUENCES, AMINO ACID;

EID: 85028909835     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M117.781112     Document Type: Article

References (57)

1. Smits, W. K., Lyras, D., Lacy, D. B., Wilcox, M. H., and Kuijper, E. J. (2016) Clostridium difficile infection. Nat. Rev. Dis. Primers 2 16020
2. Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., Wilson, L. E., Winston, L. G., Cohen, J. A., Limbago, B. M., Fridkin, S. K., Gerding, D. N., and McDonald, L. C. (2015) Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 372, 825– 834
3. McGlone, S. M., Bailey, R. R., Zimmer, S. M., Popovich, M. J., Tian, Y., Ufberg, P., Muder, R. R., and Lee, B. Y. (2012) The economic burden of Clostridium difficile. Clin. Microbiol. Infect. 18, 282–289
4. Kelly, C. P. (2012) Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin. Microbiol. Infect. 18, 21–27
5. Martin, J., and Wilcox, M. (2016) New and emerging therapies for Clostridium difficile infection. Curr. Opin. Infect. Dis. 29, 546 –554
6. Chapman, B. C., Moore, H. B., Overbey, D. M., Morton, A. P., Harnke, B., Gerich, M. E., and Vogel, J. D. (2016) Fecal microbiota transplant in patients with Clostridium difficile infection. J. Trauma Acute Care Surg. 81, 756 –764
7. Rao, K., and Young, V. B. (2015) Fecal microbiota transplantation for the management of Clostridium difficile infection. Infect. Dis. Clin. North Am. 29, 109 –122
8. Youngster, I., Mahabamunuge, J., Systrom, H. K., Sauk, J., Khalili, H., Levin, J., Kaplan, J. L., and Hohmann, E. L. (2016) Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med. 14, 134
9. Pruitt, R. N., and Lacy, D. B. (2012) Toward a structural understanding of Clostridium difficile toxins A and B. Front. Cell. Infect. Microbiol. 2, 28
10. Frisch, C., Gerhard, R., Aktories, K., Hofmann, F., and Just, I. (2003) The complete receptor-binding domain of Clostridium difficile toxin A is required for endocytosis. Biochem. Biophys. Res. Commun. 300, 706 –711
11. Chandrasekaran, R., Kenworthy, A. K., and Lacy, D. B. (2016) Clostridium difficile Toxin A undergoes clathrin-independent, PACSIN2-dependent endocytosis. PLoS Pathog. 12, e1006070
12. Qa’Dan, M., Spyres, L. M., and Ballard, J. D. (2000) pH-induced conformational changes in Clostridium difficile toxin B. Infect. Immun. 68, 2470–2474
13. Reineke, J., Tenzer, S., Rupnik, M., Koschinski, A., Hasselmayer, O., Schrattenholz, A., Schild, H., and von Eichel-Streiber, C. (2007) Autocatalytic cleavage of Clostridium difficile toxin B. Nature 446, 415– 419
14. Just, I., Selzer, J., Wilm, M., von Eichel-Streiber, C., Mann, M., and Aktories, K. (1995) Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375, 500 –503
15. Chen, S., Sun, C., Wang, H., and Wang, J. (2015) The role of Rho GTPases in toxicity of Clostridium difficile toxins. Toxins 7, 5254 –5267
16. Yang, Z., Schmidt, D., Liu, W., Li, S., Shi, L., Sheng, J., Chen, K., Yu, H., Tremblay, J. M., Chen, X., Piepenbrink, K. H., Sundberg, E. J., Kelly, C. P., Bai, G., Shoemaker, C. B., and Feng, H. (2014) A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J. Infect. Dis. 210, 964 –972
17. Yang, Z., Shi, L., Yu, H., Zhang, Y., Chen, K., Saint Fleur, A., Bai, G., and Feng, H. (2016) Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection. Pathog. Dis. 74, ftw078
18. Yang, Z., Ramsey, J., Hamza, T., Zhang, Y., Li, S., Yfantis, H. G., Lee, D., Hernandez, L. D., Seghezzi, W., Furneisen, J. M., Davis, N. M., Therien, A. G., and Feng, H. (2015) Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect. Immun. 83, 822– 831
19. Marozsan, A. J., Ma, D., Nagashima, K. A., Kennedy, B. J., Kang, Y. K., Arrigale, R. R., Donovan, G. P., Magargal, W. W., Maddon, P. J., and Olson, W. C. (2012) Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J. Infect. Dis. 206, 706 –713
20. Kyne, L., Warny, M., Qamar, A., and Kelly, C. P. (2001) Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357, 189 –193
21. Kyne, L., Warny, M., Qamar, A., and Kelly, C. P. (2000) Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342, 390 –397
22. Leav, B. A., Blair, B., Leney, M., Knauber, M., Reilly, C., Lowy, I., Gerding, D. N., Kelly, C. P., Katchar, K., Baxter, R., Ambrosino, D., and Molrine, D. (2010) Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28, 965–969
23. Giannasca, P. J., and Warny, M. (2004) Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 22, 848 – 856
24. Anosova, N. G., Cole, L. E., Li, L., Zhang, J., Brown, A. M., Mundle, S., Zhang, J., Ray, S., Ma, F., Garrone, P., Bertraminelli, N., Kleanthous, H., and Anderson, S. F. (2015) A combination of three fully human toxin A- and toxin B-specific monoclonal antibodies protects against challenge with highly virulent epidemic strains of Clostridium difficile in the hamster model. Clin. Vaccine Immunol. 22, 711–725
25. Babcock, G. J., Broering, T. J., Hernandez, H. J., Mandell, R. B., Donahue, K., Boatright, N., Stack, A. M., Lowy, I., Graziano, R., Molrine, D., Ambrosino, D. M., and Thomas, W. D. (2006) Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74, 6339 – 6347
26. Orth, P., Xiao, L., Hernandez, L. D., Reichert, P., Sheth, P. R., Beaumont, M., Yang, X., Murgolo, N., Ermakov, G., DiNunzio, E., Racine, F., Karczwski, J., Secore, S., Ingram, R. N., Mayhood, T., Strickland, C., and Therien, A. G. (2014) Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. J. Biol. Chem. 289, 18008 –18021
27. Hernandez, L. D., Kroh, H. K., Hsieh, E., Yang, X., Beaumont, M., Sheth, P. R., DiNunzio, E., Rutherford, S. A., Ohi, M. D., Ermakov, G., Xiao, L., Secore, S., Karczewski, J., Racine, F., Mayhood, T., Fischer, P., et al. (2017) Epitopes and mechanism of action of the Clostridium difficile toxin A-neutralizing antibody actoxumab. J. Mol. Biol. 429, 1030 –1044
28. Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, O. A., Rahav, G., Bouza, E., Lee, C., Jenkin, G., Jensen, W., Kim, Y.-S., Yoshida, J., Gabryelski, L., Pedley, A., et al. (2017) Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N. Engl. J. Med. 376, 305–317
29. Sauerborn, M., Leukel, P., and von Eichel-Streiber, C. (1997) The C-terminal ligand-binding domain of Clostridium difficile toxin A (TcdA) abrogates TcdA-specific binding to cells and prevents mouse lethality. FEMS Microbiol. Lett. 155, 45–54
30. Chumbler, N. M., Rutherford, S. A., Zhang, Z., Farrow, M. A., Lisher, J. P., Farquhar, E., Giedroc, D. P., Spiller, B. W., Melnyk, R. A., and Lacy, D. B. (2016) Crystal structure of Clostridium difficile toxin A. Nat. Microbiol. 1, 15002
31. Pruitt, R. N., Chambers, M. G., Ng, K. K., Ohi, M. D., and Lacy, D. B. (2010) Structural organization of the functional domains of Clostridium difficile toxins A and B. Proc. Natl. Acad. Sci. U.S.A. 107, 13467–13472
32. Ho, J. G., Greco, A., Rupnik, M., and Ng, K. K. (2005) Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A. Proc. Natl. Acad. Sci. U.S.A. 102, 18373–18378
33. Hernandez, L. D., Racine, F., Xiao, L., DiNunzio, E., Hairston, N., Sheth, P. R., Murgolo, N. J., and Therien, A. G. (2015) Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling. Antimicrob. Agents Chemother. 59, 1052–1060
34. Greco, A., Ho, J. G., Lin, S.-J., Palcic, M. M., Rupnik, M., and Ng, K. K. (2006) Carbohydrate recognition by Clostridium difficile toxin A. Nat. Struct. Mol. Biol. 13, 460 – 461
35. Murase, T., Eugenio, L., Schorr, M., Hussack, G., Tanha, J., Kitova, E. N., Klassen, J. S., and Ng, K. K. (2014) Structural basis for antibody recognition in the receptor binding domains of toxins A and B from Clostridium difficile. J. Biol. Chem. 289, 2331–2343
36. Hussack, G., Arbabi-Ghahroudi, M., van Faassen, H., Songer, J. G., Ng, K. K., MacKenzie, R., and Tanha, J. (2011) Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J. Biol. Chem. 286, 8961– 8976
37. Huang, J.-H., Shen, Z.-Q., Lien, S.-P., Hsiao, K.-N., Leng, C.-H., Chen, C.-C., Siu, L.-K., and Chong, P. C. (2015) Biochemical and immunological characterization of truncated fragments of the receptor-binding domains of C. difficile toxin A. PLoS ONE 10, e0135045
38. Krivan, H. C., Clark, G. F., Smith, D. F., and Wilkins, T. D. (1986) Cell surface binding site for Clostridium difficile enterotoxin: Evidence for a glycoconjugate containing the sequence Ga1-α1–3Gal-β1–4GlcNAc. Infect. Immun. 53, 573–581
39. Tucker, K. D., and Wilkins, T. D. (1991) Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect. Immun. 59, 73–78
40. Teneberg, S., Lönnroth, I., Torres López, J. F., Galili, U., Halvarsson, M. O., Angström, J., and Karlsson, K.-A. (1996) Molecular mimicry in the recognition of glycosphingolipids by Gal-α-3Gal-β-4GlcNAc-β-binding Clostridium difficile toxin A, human natural anti α-galactosyl IgG and the monoclonal antibody Gal-13. Glycobiology 6, 599 – 609
41. Pruitt, R. N., Chumbler, N. M., Rutherford, S. A., Farrow, M. A., Friedman, D. B., Spiller, B., and Lacy, D. B. (2012) Structural determinants of Clostridium difficile toxin A glucosyltransferase activity. J. Biol. Chem. 287, 8013– 8020
42. Ohi, M., Li, Y., Cheng, Y., and Walz, T. (2004) Negative staining and image classification: powerful tools in modern electron microscopy. Biol. Proced. Online. 6, 23–34
43. Ludtke, S. J., Baldwin, P. R., and Chiu, W. (1999) EMAN: semiautomated software for high-resolution single-particle reconstructions. J. Struct. Biol. 128, 82–97
44. Frank, J., Radermacher, M., Penczek, P., Zhu, J., Li, Y., Ladjadj, M., and Leith, A. (1996) SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields. J. Struct. Biol. 116, 190 –199
45. de la Rosa-Trevín, J. M., Quintana, A., Del Cano, L., Zaldívar, A., Foche, I., Gutiérrez, J., Gómez-Blanco, J., Burguet-Castell, J., Cuenca-Alba, J., Abrishami, V., Vargas, J., Otón, J., Sharov, G., Vilas, J. L., Navas, J., Conesa, P., et al. (2016) Scipion: A software framework toward integration, reproducibility and validation in 3D electron microscopy. J. Struct. Biol. 195, 93–99
46. de la Rosa-Trevín, J. M., Otón, J., Marabini, R., Zaldívar, A., Vargas, J., Carazo, J. M., and Sorzano, C. O. (2013) Xmipp 3.0: An improved software suite for image processing in electron microscopy. J. Struct. Biol. 184, 321–328
47. Winter, G. (2010) Xia2: An expert system for macromolecular crystallography data reduction. J. Appl. Crystallogr. 43, 186 –190
48. Waterman, D. G., Winterb, G., Parkhurst, J. M., Fuentes-Monterob, L., Hattne, J., Brewster, A., Sauter, N. K., and Evans, G. (2013) The DIALS framework for integration software. Ccp4 Newsl. Protein Crystallogr. 49, 16 –19
49. Evans, P. (2006) Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 62, 72– 82
50. Collaborative Computational Project, Number 4. (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760 –763
51. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40, 658 – 674
52. Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., et al. (2010) PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221
53. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486 –501
54. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004) UCSF Chimera: a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612
55. Morin, A., Eisenbraun, B., Key, J., Sanschagrin, P. C., Timony, M. A., Ottaviano, M., and Sliz, P. (2013) Collaboration gets the most out of software. Elife 2, e01456
56. Krissinel, E., and Henrick, K. (2007) Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774 –797
57. de Beer, T. A., Berka, K., Thornton, J. M., and Laskowski, R. A. (2014) PDBsum additions. Nucleic Acids Res. 42, D292–D296